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Congenital erythropoietic porphyria (CEP) is due to a deficiency in the enzymatic activity of uroporphyrinogen III synthase (UROS);
such a deficiency leads to porphyrin accumulation and results in skin lesions and hemolytic anemia. CEP is a candidate for retro-
lentivirus-mediated gene therapy, but recent reports of insertional leukemogenesis underscore the need for safer methods. The discovery
of induced pluripotent stem cells (iPSCs) has opened up new horizons in gene therapy because it might overcome the difficulty of
obtaining sufficient amounts of autologous hematopoietic stem cells for transplantation and the risk of genotoxicity. In this study,
we isolated keratinocytes from a CEP-affected individual and generated iPSCs with two excisable lentiviral vectors. Gene correction
of CEP-derived iPSCs was obtained by lentiviral transduction of a therapeutic vector containing UROS cDNA under the control of an
erythroid-specific promoter shielded by insulators. One iPSC clone, free of reprogramming genes, was obtained with a single proviral
integration of the therapeutic vector in a genomic safe region. Metabolic correction of erythroblasts derived from iPSC clones was
demonstrated by the disappearance of fluorocytes. This study reports the feasibility of porphyria gene therapy with the use of iPSCs.Introduction
Congenital erythropoietic porphyria (CEP [MIM 263700])
is an autosomal-recessive disorder characterized by
a profound deficiency in the enzymatic activity of uropor-
phyrinogen III synthase (UROS; EC 4.2.1.75), the fourth
enzyme of the heme biosynthetic pathway.1,2 The enzy-
matic defect causes the accumulation of the nonphysiolog-
ical porphyrin isomer uroporphyrin I. The lack of UROS
causes mutilating dermatological lesions resulting from
the release of photocatalytic porphyrins and transfusion-
dependent hemolytic anemia with massive secondary
hypersplenism. The clinical severity of the disease and the
lack of specific treatment—apart from when bone marrow
(BM) transplantation with a histocompatibility leukocyte
antigen (HLA)-compatible donor is available3–8—are
strong arguments for gene therapy.2 We, as well as
others,9–11 have generated an animal model of CEP in
order to study the pathophysiology of the disease and to
evaluate the feasibility of stem cell and gene therapy for
this disease. Lentivirus-mediated transfer of the human
therapeutic UROS cDNA into hematopoietic stem cells
(HSCs) from homozygous Urosc.744C>A/c.744C>A-knockin
mice (p.Pro248Gln) (the Uros RefSeq accession number is
NM_009479.2) resulted in the complete and long-term
enzymatic, metabolic, and phenotypic correction of the
disease. This correction is favored by the survival advan-
tage of corrected red blood cells.12 This data supports the
proof of concept of a successful gene therapy for this
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The AmGene-transfer technologies have now been successfully
used in clinical gene-therapy applications formany genetic
diseases,13–19 but recent reports of proviral insertional
leukemogenesis underscore the need for safer methods.20
The discovery of key transcription factors enabling
reprogramming of a somatic cell into a pluripotent stem
cell, called an induced pluripotent stem cell (iPSC),
has provoked an exciting rebound in gene-therapy
research.21–24 Gene-therapy model systems based on iPSCs
have been created for a wide range of hereditary hemato-
logic disorders, such as Fanconi anemia (MIM 227650),25
sickle-cell anemia (MIM 141900),26 thalassemia (MIM
613985),27 and hemophilia B (MIM 306900).28 Because
iPSCs can be maintained indefinitely in vitro, they repre-
sent an unlimited source of cells, and this surmounts the
difficulty of obtaining sufficient amounts of autologous
HSCs for transplantation. Moreover, the clonal approach
allowed by iPSCs could overcome the risk of insertional
oncogenesis by the characterization of proviral integration
sites (ISs) of the therapeutic vectors and the selection of
iPSC clones with ISs in a genomic safe harbor (GSH).27,29
The main goal of this project was to evaluate whether
iPSCs might provide a key cell resource for gene therapy
in a CEP model. To achieve this goal, we derived human
iPSCs with epidermal keratinocytes taken from a CEP-
affected individual by using excisable lentiviral vectors.
Excised iPSC clones, free of reprogramming factors, were
corrected (gene additive therapy). All ISs were found in
nononcogenic genes, and one IS was found without
cancer-related genes nearby. Then, they were differentiateds des Maladies Ge´ne´tiques et Cancers, Laboratoire d’Excellence du Globule
rdeaux, France; 3Vectorology Platform, Structure Fe´de´rative de Recherche
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Figure 1. CEP Characterization and
Schematic Drawing of iPSC Generation
(A) Genotyping of keratinocytes from
a CEP-affected individual compound
heterozygous for UROS mutations
c.217T>C (p.Cys73Arg) and c.683C>T
(p.Thr228Met).
(B) Schematic representation of the
proviral form of the lentivectors used.
OSK 1 is an excisable single polycistronic
vector coexpressing OCT4, SOX2, and
KLF4 cDNAs linked with the porcine
teschovirus-1 2A sequence. Mshp53 coex-
presses MYC and a shRNA against TP53;
both vectors are flanked by loxP sites.
HAUPins contains the UROS cDNA under
the control of the erythroid chimeric
HS-40 enhancer/ankyrin promoter. Arrows
show the position of forward (F) and
reverse (R) primers used for proviral inte-
gration analyses. The following abbrevia-
tions are used: HS40, enhancer of HBA1
(MIM 141800); Ank p, ankyrin promoter
of ANKYRIN-1 (MIM 612641); UROS,
cDNA of uroporphyrinogene III synthase;
H1p, mammalian polymerase III H1
promoter; EF1a-p, elongation factor-1 alpha
promoter; WPRE, woodchuck posttran-
scriptional regulatory element; PRE, a
mutated WPRE sequence (WPREmut6);
and cHS4, element of the chicken b-globin
hypersensitivity site 4.
(C) Schematic strategy used for reprogram-
ming human keratinocytes from a CEP-
affected person and for HSC differentia-
tion. The following abbreviations are
used: HD, hematopoietic differentiation;
and ED, erythroid differentiation.into HSCs. Enzymatic and metabolic corrections were
obtained in erythroid cells derived from corrected CEP
iPSC clones. This study is a proof of principle of a safe
iPSC-mediated gene therapy for CEP.Material and Methods
Lentiviral Constructions and Productions
Two lentiviral vectors were used for iPSC generation (OSK 1 and
Mshp53) (Figure 1B). The polycistronic pKP332 (Lenti-OSK1)
vector (OSK 1) was obtained from Addgene (plasmid 21627).
OCT4 (POU5F1 [MIM 164177]), SOX2 (MIM 184429), and KLF4
(MIM 602253) cDNAs, linked with porcine teschovirus-1 2A
sequences, were under the control of the EF1-a promoter in
a self-inactivating (SIN) lentiviral vector containing a Lox P site
in the truncated 3’ long terminal repeat (LTR).30 We constructed
Mshp53 containingMYC (MIM 190080) cDNA and shRNA against
TP53 (MIM 191170) as follows: MYC from a lentiviral Cre-Lox
pMXs-hc-MYC plasmid (17220 from Addgene) was digested by
NotI and inserted into a subcloning vector to flank the cassette
with EcoRI and BamH1 restriction sites. The EGFP cassette from
pLVTH-siP53 (12239 from Addgene) was removed with EcoRI
and BamHI and replaced by the insert of MYC under the control
of the EF1- a promoter.
The therapeutic lentiviral vector HAUPins has been previously
described31 and is derived from the original HAUW vector con-110 The American Journal of Human Genetics 91, 109–121, July 13, 2taining UROS cDNA under the control of the chimeric HS40-
Ankyrin promoter, a vector already used in gene therapy in the
CEP mouse model.12 In brief, HAUPins is different from HAUW
in that it contains (1) the insertion of a mutated WPRE sequence
(PRE) without the potentially oncogenic WPRE-X32 and (2) the
insertion of the 50 cHS4 insulator in the DU3 sequence of the 30
LTR.33 The HAEPins control vector contains exactly the same
backbone but has EGFP instead of UROS cDNA (Figure 5C).
VSV-G pseudotyped lentivectors were produced by triple tran-
sient transfection in 293T cells and were concentrated by ultrafil-
tration (Vivaspin 20, Sartorius Biotech SA, USA) as previously
described.12 To determine viral production, we measured human
immunodeficiency virus (HIV) p24 titles in the concentrated viral
supernatant by ELISA assay (Innotest HIV, p24, Innogenetics,
France). We estimated viral titers by comparing p24 antigen levels
of each lentiviral supernatant with a green fluorescent protein
(GFP) lentiviral supernatant produced simultaneously. Superna-
tants were found to be free of replication-competent virus.
Source of Somatic Cells for Human iPSC Generation
and Transduction
Keratinocytes were isolated from a CEP-affected person and
a healthy person undergoing plastic surgery after informed
consent was obtained in accordance with the ethical standards
of the responsible committee on human experimentation (Centre
Hospitalier Universitaire de Bordeaux). Skin fragments were
treated with trypsin-EDTA for 3 hr at 37C for the separation of012
the epidermis from the dermis. Keratinocytes were seeded at
a concentration of 105 cells per cm2 in MCDB153 medium, which
included hydrocortisone (0.5 mg/ml), epidermal growth factor
(10 ng/ml), insulin (5 mg/ml), and bovine pituitary extract
(70 mg/ml) (all from Sigma). For reprogramming, keratinocytes
were seeded at a concentration of 105 cells per well (in a 6-well
plate) and were cotransduced 24 hr later with a combination of
OSK 1 and Mshp53 lentivectors at a multiplicity of infection
(MOI) of 10. After an additional 2 day culture in the samemedium,
cells were transferred onto mitomycined mouse embryonic fibro-
blasts (MEFs) and cultured in the embryonic stem (ES) medium
described below.
CD34þ cells from a cord-blood sample were obtained after
informed consent was obtained according to procedures approved
by the Bagatelle Hospital review board. Mononuclear cells were
isolated by Ficoll gradient. CD34þ cells were purified according
to the manufacturer’s (Miltenyi Biotech) instructions. Purity was
analyzed by flow cytometry with a phycoerythrin-conjugated
CD34 antibody (Becton Dickinson). CD34þ cells were cultured
2 days in expansion medium consisting of Stem Span SFEM
(STEMCELL Technologies, Grenoble, France) supplemented with
Flt3-L (50 ng/ml), SCF (50 ng/ml), and human TPO (50 ng/ml)
(all from Peprotech, Rocky Hill, NJ, USA). For reprogramming,
CD34þ cells were cotransduced with a combination of the two
reprogramming lentivectors at a MOI of 100. After an additional
2 day culture in the same expansion medium, cells were trans-
ferred onto mitomycined MEFs and cultured in ES medium.
For keratinocytes and CD34þ cells, the individual iPSC-like
colonies were picked up from days 14–21 for expansion. iPSC-
like colonies from human skin fibroblasts were obtained with
the same two lentivectors at a MOI of 30 and were later picked
up from week 5 to week 6.Human iPSC Culture
Human iPSC clones were maintained as undifferentiated cells in
cocultures with mitomycined MEFs. The ES medium used was
the following: KO-DMEM (Invitrogen, Villebon sur Yvette, France)
containing 20% KOSR (Invitrogen) (vol/vol), 15 ng/ml human
bFGF (Peprotech), 1 mM GlutaMAX (Invitrogen), 100 mM Non-
Essential Amino Acids (Invitrogen), 100 mM 2-mercaptoethanol
(Sigma-Aldrich, Saint Louis, MO, USA), 50 mg/ml ascorbic
acid (Sigma-Aldrich), 0.5 mM sodium butyrate (Sigma-Aldrich),
50 U/ml penicillin, and 50 mg/ml streptomycin (Invitrogen).
The ES medium was changed every day.iPSC Characterization
Substrate staining for alkaline phosphatase (ALP) was carried out
with a leukocyte ALP staining kit (Sigma-Aldrich).
For the detection of pluripotency markers, cells grown in
24-well plates were fixed by 4% paraformaldehyde and permeabi-
lized with ice-cold 0.2% Triton X-100 in PBS. After saturation with
0.2% PBS-triton and 1%HSA, cells were stained with primary anti-
bodies for 1 hr and were then incubated with a second fluoro-
chrome-labeled antibody (Alexa Fluor, Invitrogen). The primary
antibodies used were: OCT4 (clone C-10, Santa Cruz,CA, USA),
SOX2 (Abcam, Cambridge, UK), KLF4 (Abcam), NANOG (Abcam),
SSEA-4 (clone 813-70, STEMCELL Technologies), and TRA1-60
(STEMCELL Technologies).
For RT-PCR analysis of pluripotency markers, total RNA from
iPSC clones and primary cells (CD34þ cells, keratinocytes, and
fibroblasts) was isolated with TRIZOL reagent (Invitrogen). RT-PCRThe Am(27 cycles) was performed after RNase-free DNase pretreatment
with a first-Strand cDNA synthesis kit for RT-PCR (Roche Applied
Science, Meylan, France) and with oligonucleotides described by
Papapetrou et al.27
For teratoma induction, iPSCs were plated in a 10 cmMEF feeder
dish. At day 6, approximately 2 3 106 cells were harvested, resus-
pended in 100 ml of ES medium containing 10 mMof the Rho-asso-
ciated kinase (Rock) inhibitor Y-27632 (Sigma), and injected into
NOD Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NOD-SCID IL2Rg null:NSG)
mice (subcutaneous space). The NSG mice were produced and
housed in the University Bordeaux Segalen animal facility accord-
ing to the rules and regulations governed and enforced by
the Institutional Animal Care and Use Committee. The animal
facility’s institutional agreement number is A33063916. Animals
were included in protocols between the ages of 6 and 8 weeks.
Teratomas were harvested 8–12 weeks after injection. Paraffin-
embedded tissue was sliced and stained with Alcian blue.
Karyotyping
After FrdU synchronization followed by a thymidine chase,
standard R-banding analysis was performed on metaphase chro-
mosomes obtained with all iPSC clones. At least 20 metaphase
chromosomes were fully karyotyped.
Cre-Mediated Vector Excision
IPSC clones were transduced twice at an MOI of 100 with a Cre-
expressing adenovirus (kindly provided by the Association
Franc¸aise contre les Myopathies, Ge´ne´thon). At day 7, iPSCs
were dissociated into single cells with accutase (STEMCELL
Technologies) and cloned by a limiting dilution. Cre-Lox excision
of proviral reprogramming cassettes was checked in each subclone
by multiple PCR analyses. Primers used were designed by Primer3
software for both proviruses, and their positions in OSK 1 and
Mshp53 are shown in Figure 1B. All oligonucleotide sequences
are provided in Table S1, available online.
Quantitative PCR Detection of HAUPins Provirus
DNAwas isolatedwith the NucleoSpin Tissue kit (Macherey-Nagel,
Hoerdt, France) from 1 3 106 cells, and real-time PCR was per-
formed on 100 ng of DNA with the use of Taqman technology
(Applied Biosystems, Foster City, CA). DNA from nontransduced
cells was isolated and amplified at the same time for demon-
strating the absence of contamination. Samples were heated to
50C for 2 min and to 95C for 10 min, and then 40 cycles of
PCR were performed for 15 s at 95C and for 1 min at 60C.
UROS amplimers are described in Table S1. RNaseP was used for
normalization (Applied Biosystems, Foster City, CA). DNA from
two different cell clones (human 293T and K562 cells), containing
a single integrated copy of the transgene, was used as a standard.
Characterization of Proviral Integration Site
by LAM-PCR
For the identification of genomic proviral ISs, linear amplification-
mediated PCR (LAM-PCR) was performed as previously
described34 with 100 ng of DNA from each iPSC clone. Linear
PCR was carried out with biotinylated primer LTRI*. Selection of
biotinylated extension products was performed with magnetic
beads according to the manufacturer’s (Invitrogen Dynal AS,
Oslo, Norway) instructions. After double-stranded DNA synthesis,
Tsp509I was used as the restriction enzyme, and a double-stranded
asymmetric linker cassette was linked with LC1 and LC3 linkers.erican Journal of Human Genetics 91, 109–121, July 13, 2012 111
The first exponential PCR was carried out with linker-cassette
primer LCI and vector-specific primer LTRII*, whereas the second
exponential PCR was carried out with internal primers LCII and
LTRIII. PCR products were cloned into the TOPOTA cloning vector
(Invitrogen, Carlsbad, CA) and sequenced. Sequences obtained
were aligned by BLAST with the human genome.
ISs were confirmed by PCR with the forward primer specific to
the cHS4 insulator sequence and the reverse primers specific to
the genomic sequence adjacent to the integration (all oligonucle-
otides are provided in Table S1).
The proximity of ISs to proto-oncogenes was determined by
comparison with the allOnco database.
Hematopoietic Differentiation of iPSCs
Hematopoietic differentiation of iPSCs was performed as described
by Woods et al.35 with modifications. In brief, we first generated
embryonic bodies (EBs). From day 0 to day 2, iPSCs were harvested
and placed in EB medium (IMDM medium, 15% fetal bovine
serum [FBS], 1%nonessential amino acid) overnight on nonadher-
ent cell-culture dishes. Then, to induce mesodermal transition, we
cultured newly generated EB colonies onmitomycined OP9 feeder
cells (CRL-2749 from ATCC, Manassas, VA, USA) on Matrigel (BD
Biosciences) for 12 additional days; we partially changed the
medium every day in a mesodermal-specifying medium (DMEM/
F12, 15% FBS with BMP4, low doses of VEGF, TPO, EPO, SCF,
and Flt3L [all from Peprotech at the same concentrations described
byWoods et al.35], holotransferrine and ascorbic acid [from Sigma-
Aldrich], and PGE2 [Cayman Chemical]). From day 14 to day 21 of
hematopoietic differentiation, mediumwas changed to serum-free
expansionmedium (STEMCELLTechnologies) supplemented with
TPO, EPO, SCF, Flt3L, and PGE2 for the promotion of hematopoi-
etic differentiation and HSC expansion. Fluorescence-activated
cell sorting (FACS) analysis of CD34þ and CD45þ cells was per-
formed at day 21 for the evaluation of hematopoietic-differentia-
tion efficiency.
Hematopoietic Colony Formation in Methylcellulose
Single-cell suspensions of hematopoietic cells were plated
in a methylcellulose-based medium of MethoCult H4435
(STEMCELL Technologies) (approximately 105 cells) in 6-well
plates. At day 14, colonies were scored by bright-field microscopy
and fluorescence for the visualization of fluorocytes and GFP
expression. Fluorescent images were acquired with a Nikon
ECLIPSE Ti inverted microscope and captured with a digital sight
camera and NIS-element imaging software.
Erythroid Differentiation
For erythroid differentiation, we performed a 3 week protocol after
hematopoietic differentiation. In brief, cells were seeded in a
6-well low attachment plate with erythroid medium (Stem-alpha
AE base [Stem Alpha, France] supplemented with 5% human
plasma, 5 U/ml Epo, 50 ng/ml SCF from Peprotech, 1 mg/ml
holotransferrine, 106 M dexamethasone, 20 ng/ml insulin, and
104 M b-mercapto-ethanol [Sigma Aldrich]). Hemoglobin anal-
ysis was performed by HPLC (Variant II, Bio-Rad). FACS analysis
of CD71þ and GPAþ cells was performed at day 21 for the evalua-
tion of erythroid-differentiation efficiency.
Flow Cytometry
Cells were individualized from the differentiation cultures,
collected, and washed with 1% PBS-HSA. Cells were stained with112 The American Journal of Human Genetics 91, 109–121, July 13, 2phycoerythrin (PE)- or allophycocyanin (APC)-conjugated anti-
CD34, PECy5- or PE-conjugated anti-CD45, PE-conjugated anti-
CD14, APC-conjugated anti-CD19, PE-conjugated anti-CD33,
PE-conjugated anti-CD71, and APC-conjugated anti-GpA (all
from BD, Franklin Lakes, NJ, USA).
Fluorocytes were analyzed at 550 nm emission wavelength with
a 405 nm excitation laser. Cells were analyzed on a FACS flow
cytometer (Canto II, BD, San Jose, CA, USA).
UROS Enzymatic Activity and Metabolic Correction
UROS activity was determined by an enzyme-coupled assay as
described previously.36 One unit was defined as the amount of
enzyme that formed 1 nmol of uroporphyrinogen III per hour at
37C.
Statistical Analysis
Results are expressed as mean 5 standard deviation (SD). Statis-
tical tests were performed with Student’s t tests. p < 0.05 was
considered statistically significant.Results
Generation of iPSCs
Primary human epidermal keratinocytes were isolated
from the skin of a healthy donor undergoing plastic
surgery and from a skin biopsy from a CEP-affected indi-
vidual after informed consent was obtained. Genetic
testing revealed that the CEP-affected individual was
compound-heterozygous for UROS (RefSeq NG_011557.1)
mutations c.217T>C (p.Cys73Arg) and c.683C>T
(p.Thr228Met), thus confirming the diagnosis of CEP
(Figure 1A). The residual enzymatic activity measured by
an enzyme coupled assay was below 2% of the normal
level.
To increase the yield of iPSC generation, we designed the
Mshp53 vector carrying the coexpression of MYC under
the control of EF1-a promoter and a shRNA against TP53
under the control of the H1 promoter (Figure 1B). In addi-
tion to the expression of the four standard reprogramming
factors, the repression of TP53 has been previously re-
ported to improve the efficiency of the reprogramming
process.37 iPSC generation was obtained by transduction
of normal and deficient keratinocytes with the two SIN
lentivectors (OSK 1 and Mshp53, Figure 1B). Colonies
with ES-like morphology from normal keratinocytes (N-K
iPSCs) and CEP keratinocytes (CEP-K iPSCs) were picked
from days 14–21 (Figure 1C). Fibroblasts were also trans-
duced for reprogramming as controls. In addition to
transduction of these cells, transduction of neonatal
CD34þ cells from umbilical-cord blood cells was performed
for generating control iPSCs for further hematopoietic
differentiation.
Generation of iPSC clones from keratinocytes was ten
times more efficient than that from control skin fibroblasts
(0.4% versus 0.04%, respectively) and was faster (picked
from days 14–21 versus days 35–42 for fibroblasts).
Although OSK 1 vector transduction alone led to efficient
reprogramming with murine fibroblasts,30 the use of this012
Figure 2. Characterization of iPSC
Clones
(A) Representative immunofluorescence of
pluripotency markers in human iPSC
clones derived from normal CD34þ CB
cells (N-CB iPSC 10) and in keratinocytes
derived from a normal individual (N-K
iPSC 21) and a CEP-affected individual
(CEP-K iPSC 3 and CEP-K iPSC 4); staining
is with anti-OCT4, anti-SOX2, anti-KLF4,
anti-NANOG, anti-SSEA-4, and anti-
TRA1-60. MEFs surrounding human
iPSCs served as a negative control for
immunofluorescence (magnification3100
or 3200).
(B) Expression of pluripotency-associated
genes (OCT4, SOX2, NANOG, ESG1,
DNMT3B, REX1, HTERT, DPPA4, and
CRIPTO) by RT-PCR cycles (28) from two
independent CEP-K iPSC clones and two
N-CB iPSC clones. Primary N-K cells and
primary normal human fibroblast (N-
Fibro) cells were used as controls. GAPDH
served as an internal positive control.
The following abbreviation is used: Blk,
blank (PCR performed without cDNA).
(C) Alcian-blue staining of histological
sections of a representative teratoma
derived from human CEP-K iPSC 4 shows
tissues of all three germ layers (magnifica-
tion3200).
(D) Representative karyotypic analysis of
two human CEP-K iPSC clones (CEP-K
iPSC 3 and CEP-K iPSC 4).single vector failed to generate stable iPSC clones from
human cells. Indeed, the addition of the Mshp53 vector
was mandatory for achieving the terminal reprogramming
and generating high-quality iPSC clones. Efficiency and
kinetics of keratinocyte reprogramming were quite similar
to neonatal normal CD34þ cells (N-CB iPSCs). All the colo-
nies harvested demonstrated the typical characteristics of
pluripotent stem cells, i.e., similar morphology to human
ES cells, strong alkaline-phosphatase activity (data not
shown), and expression of pluripotent stem cell markers,
such as OCT3/4, SOX2, KLF4, NANOG, SSEA-4, and
TRA1-60 (Figure 2A), as evidenced by immunocytochem-
istry. We isolated a total of 23 iPSC clones from keratino-
cytes (N-K iPSCs and CEP-K iPSCs), fibroblasts, or normal
CD34þ cells (N-CB iPSCs). Four putative iPSC clones (two
CEP-K iPSCs [3 and 4] and two N-CB iPSCs [10 and 11])
were kept for further characterization. RT-PCR analysis re-
vealed that the endogenous pluripotency-associated genes
NANOG (MIM 607937), ESG1 (TLE1 [MIM 600189]),
DNMT3B (MIM 602900), REX1 (ZFP42 [MIM 614572]),The American Journal of HumanTERT (MIM 187270), DPPA4 (MIM
614125), and CRIPTO (TDGF1 [MIM
187395]) were robustly expressed in
the isolated colonies (Figure 2B).
iPSC xenografts into immunodefi-
cient NSGmice resulted in the forma-
tion of teratomas, and all threeembryonic germ layers demonstrated in vivo pluripotency
of the iPSC clones (Figure 2C). Karyotypic analyses
confirmed the absence ofmacroscopic genetic abnormality
in all the tested iPSC clones (Figure 2D) except for CEP-K
iPSC 3, in which there was a minor abnormality (some
mitosis with one X chromosome deletion) (Figure 2D,
left panel). As a precaution, this iPSC clone was kept as
an uncorrected control for further experiments.
Generation of Safe and Corrected iPSC Clones
without Exogenous Reprogramming Factors
To develop safe iPSCs without exogenous reprogramming
factors, we excised the reprogramming cassettes, flanked
by the loxP sites, by adenovirus-mediated CRE recombi-
nase expression in the four iPSC clones tested (Figure 1C).
After subcloning the four iPSCs (two CEP-K iPSCs [3 and 4]
and two N-CB iPSCs [10 and 11]), we performed a DNA-
PCR analysis to select clones with excision of both reprog-
ramming cassettes (Figure 3A, upper panel). To check
the absence of additional recombination with portions ofGenetics 91, 109–121, July 13, 2012 113
Figure 3. Characterization of iPSC
Clones Free of Reprogramming Trans-
gene
(A) Upper panel: PCRs for the integrated
vectors OSK 1 and Mshp53 in seven
CEP-K iPSC 4 subclones pretreated by
CRE adenovirus (subclones are A, B, C, D,
E, F, and I). Lower panel: Multiple PCRs
performed on DNA from the three excised
clones (C, E, and I) and the nonexcised
iPSC 4 with seven couples of primers
described in (B) for detecting the presence
of portions of the recombinant provirus.
(B) Expression of pluripotency-associated
genes by RT-PCR from three independent
iPSC subclones from CEP-K iPSC 4 and
one iPSC subclone from N-CB iPSC 10.
(C) Chromosome ideograms and graphics
depicting 300 kb of the human genome
on both sides of the proviral IS (in green)
of HAUPins from CEP-K iPSC 4-c (upper
panel), from CEP-K iPSC 4-e (middle
panel), and from CEP-K iPSC 4-i (lower
panel). Graphics were obtained with the
UCSC Genome Graphs tool. All known
genes present in the genomic region are
shown (genes implicated in cancer accord-
ing to the allOnco database are shown
in red).
(D) Representative immunofluorescence
of pluripotency markers in human iPSC
clones that are free of reprogramming
transgene and derived from CEP-K iPSC
4-c and 4-i (magnification 3100 or 3200).
(E) Karyotypic analysis of the two excised
clones (4-c and 4-i).
(F) Alcian-blue staining of histological
sections of a teratoma derived from
human CEP-K iPSC 4-c, free of reprogram-
ming transgene, shows tissues of all three
germ layers.the reprogramming vectors in the three excised clones (4-c,
4-e, and 4-i), we used an additional set of multiple primers
all along both proviruses (Figure 3A, lower panel). Gene
correction of CEP-K iPSC 4 was then obtained by lentiviral
transduction with a HAUPins vector. This vector contains
the UROS cDNA sequence under the control of the
chimeric HS40 enhancer/ ankyrin-1 erythroid-specific pro-
moter and is shielded by cHS4 insulators in the LTR
(Figure 1B). Subsequently, we tested excised subclones
fromCEP-K iPSC 4 by quantitative-PCR analysis to identify
those with only one copy of the HAUPins vector. The
sequencing of the proviral IS after LAM-PCR allowed us
to locate the IS of HAUPins (Figure 3C). For corrected
subclone 4-c, the IS is located on chromosome 1 (position
148,683,731, orientation þ) in the sixth intron of RPRD2.
For corrected subclone 4-e, the IS is located on chromo-114 The American Journal of Human Genetics 91, 109–121, July 13, 2012some 11 (position 64,963,338, orien-
tation þ) in the tenth intron of
CAPN1 (MIM 114220). For corrected
subclone 4-i, the IS is located on chro-
mosome 3 (position 17,418,684,orientation þ) in the fifth intron of TBC1D5. Graphics de-
picting 600 kb of human genome of the IS region for each
clone and all genes present are shown in Figure 3C. Sixteen
genes, including three cancer-related genes (APH1A [MIM
607629], ECM1 [MIM 60220], and MCL1 [MIM 159552];
all labeled in red in Figure 3C, upper panel) were found
in the 600 kb region around the IS of clone 4-c. In the
same way, twenty-eight genes, including three cancer-
related genes (SLC22A20 [MIM 611696], CDC42EP2
[MIM 606132], and FRMD8 [Figure 3C, middle panel])
were found near the IS of clone 4-e. In contrast, only two
genes (neither of them related to cancer) were found in
the 600 kb region of the 4-i IS (Figure 3C, lower panel).
Then, we eliminated clone 4-e because of the density
of genes in the neighbor of the IS. Characterization of
the four excised iPSC clones (4-c, 4-e, 4-i, and 10-f) by
Figure 4. Efficient Hematopoietic Differ-
entiation of iPSCs
(A) Representative FACS analysis of CD45þ
and CD34þ cells obtained from N-CB iPSC
10-f (upper panels) and CEP-K iPSC 4-c
(lower panels), both free of reprogram-
ming transgenes, after hematopoietic
differentiation (at day 21) in nonadherent
fraction (left panels) and in adherent
fraction (right panels) from the same
experiment.
(B) Bar graphs show the average percent-
ages of CD45þ, CD34þ, and CD34þ and
CD45þ cells obtained from four iPSC
clones (N-CB iPSC 10-f, uncorrected
CEP-K iPSC 3, and corrected CEP-K iPSCs
4-i and 4-c) in nonadherent fractions (left
panel) and in adherent fractions (right
panel) at day 21 of hematopoietic differen-
tiation (n ¼ 5 independent experiments,
mean 5 SD). No statistical difference was
observed between clones.
(C) Bright-field microscopy of CFUs (a
granulocytic CFU [CFU-G], a monocytic
CFU [CFU-M], and an erythroid burst-
forming unit [BFU-E]) in methylcellulose
medium by hematopoietic cells obtained
from uncorrected (upper panel) or cor-
rected (lower panel) CEP-K iPSCs (magnifi-
cation 3100).
(D) Inverted microscopy of a BFU-E in
methylcellulose derived from the uncor-
rected CEP-K iPSC 3 under visible (upper
panel) or UV light (lower panel).RT-PCR (Figure 3B), immunocytochemistry (Figure 3D),
and teratoma assays (Figure 3F) confirmed that the sub-
clones retained their pluripotency. No abnormality was
found by new karyotypic analysis (Figure 3E).
Differentiation of iPSCs into HSCs
To generate hematopoietic cells, including hematopoietic
stem and progenitors cells (HSPCs), we used the optimized
3 week protocol described by Woods et al.35 with some
modifications (days 1–21, Figure 1C). At day 21, after
hematopoietic differentiation, we obtained hematopoietic
cells (CD45þ) derived from all iPSC clones but with various
yields of hematopoietic cells (CD45þ) depending on the
cell fractions (in adherent or nonadherent compartments)
(Figures 4A and 4B).The American Journal of HumanIn the nonadherent fraction, high
yields of CD45þ cells were obtained
without a significant difference
between clones: N-CB iPSC 10-f had
a mean of 50.7%, CEP-K iPSC 3
had a mean of 22.8%, CEP-K iPSC 4i
had a mean of 43%, and CEP-K iPSC
4c had a mean of 21.8% (Figures 4A
and 4B, left panels). For the CD34þ
and CD45þ population, we observed
a higher mean of percentage for cells
derived from N-CB iPSCs than forcells derived from K iPSCs, but there was no significant
difference: N-CB iPSC 10-f had a mean of 14%, CEP-K-
iPSC 3 had a mean of 1.1%, CEP-K iPSC 4i had a mean of
4.5%, and CEP-K-iPSC 4c had a mean of 3.5% (Figure 4B,
left panel).
In the adherent fraction, no difference in hematopoietic-
differentiation efficiency was observed for percentages of
CD45þ cells and CD34þ and CD45þ cells between iPSCs
derived from keratinocytes and those derived from cord-
blood cells (Figure 4B, right panel). Interestingly, however,
we found that the mean fluorescent intensity (MFI) of
CD34-APC signals was ten times higher in the adherent
fraction than in the nonadherent counterpart (Figure 4A).
A more complete cell-surface-marker signature was real-
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from the corrected CEP-K iPSC 4-i clone. FACS analysis
showed the presence of myeloid cells (CD33þ: 29.5%),
monocytes (CD14þ: 27.1%), erythroid cells (CD71þ and
GPAþ: 11.2%), and B lymphoid cells (CD19þ: 2.6%).
In addition to performing cell-surface-marker analysis,
we performed colony-forming unit (CFU) assays and
observed erythroid burst-forming units (BFU-Es) and CFU
granulocyte/monocyte (CFU-GM) colonies derived from
all iPSC clones (Figure 4C). As a result of spontaneous
porphyrin accumulation, BFU-Es from uncorrected CEP-K
iPSC 3 fluoresced in red when viewed under UV light (exci-
tation light 405 nm) (Figure 4D, lower panel), whereas
BFU-Es from normal N-CB iPSCs, corrected CEP iPSC 4-c,
and CEP iPSC 4-i did not fluoresce. A 3 week in vitro
erythroid differentiation was then performed from nonad-
herent hematopoietic cells (Figure 1C). A very efficient
erythroid differentiation was obtained (from 10% CD71þ
and glycophorin-Aþ at day 10 to 76% at day 17, for exam-
ple, with CEP-K iPSC 4i) (Figure 5A). Cytological examina-
tion revealed abundant basophilic and polychromatic
erythroblasts without enucleation (Figure 5B). HPLC
analysis showed that these erythroblasts contained mainly
fetal hemoglobin, but not adult hemoglobin (not shown).
Enzymatic and Metabolic Rescue
of the Corrected Cells
After reprogramming, it is possible that epigenetic modifi-
cations induce silencing of the transgene promoter carried
by a lentiviral vector. In our model, rescue of UROS activity
was dependent on the activity of the HS40/Ank promoter
during erythropoiesis. So, we first analyzed whether the
chimeric HS40/Ank promoter was still functional and
erythroid specific in our iPSC differentiation model. To
carefully verify this main prerequisite, we transduced
the N-CB iPSC 10-f clone with the HAEPins lentivector
(the same as HAUPins but with EGFP cDNA instead of
UROS cDNA [Figure 5C]) at a MOI of 10. Erythroid-specific
GFP expression was confirmed by FACS analysis at day 21,
when the hematopoietic differentiation was complete.
Almost all GFPþ cells were Glycophorin Aþ and had a
highMFI, confirming the erythroid specificity of the vector
in the iPSC model (Figure 5D). Surprisingly, inverted fluo-
rescence microscopy at the early stage of hematopoietic
differentiation (between days 10 and 14) revealed the
presence of erythroid progenitor cells contained in sacs
on the OP9 feeder cells; these sacs resembled the yolk sac
described in early erythropoiesis during embryogenesis
(Figure 5E, middle and left panels). These cells were found
in the supernatant medium at day 21 (Figure 5E, right
panel). GFPþ BFU-E colonies in methylcellulose assays
were observed under an inverted microscope (Figure 5F).
The residual UROS activity in primary CEP keratinocytes
used for iPSC generation was much lower than that
in normal primary keratinocytes (<0.2 U/mg protein,
Figure 6A). We performed quantification of UROS enzy-
matic activity of erythroid cells derived from iPSCs
21 days after the induction of erythroid differentiation.116 The American Journal of Human Genetics 91, 109–121, July 13, 2In erythroid cells derived from N-CB iPSC 10-f, a high level
of enzymatic activity was observed in erythroblasts as a
result of the strong activity of the endogenous erythroid-
specific UROS promoter from the two alleles (mean ¼
46.35 9.6 U/mg protein). By contrast, the erythroid cells
from the uncorrected CEP iPSC 3 displayed very low levels
of UROS activity (below <1 U/mg protein). We observed
that the enzymatic activity in erythroid cells from the cor-
rected clone (4-i) was six times higher than that in cells
from the uncorrected clone 3 (mean ¼ 5.2 5 0.9 U/mg
protein) (Figure 6 A).This activity represents 11% of the
UROS activity of the erythroid cells derived from N-CB
iPSCs and 52% of the UROS activity of normal keratino-
cytes (Figure 6A). To examine whether this partial enzy-
matic correction was translated into a metabolic rescue,
we looked at the proportion of fluorocytes at the end of
erythroid differentiation. Spontaneous accumulation of
porphyrins in erythroid cells derived from the uncorrected
CEP-K iPSC 3 clone resulted in a high percentage of fluoro-
cytes (47.3% 5 1.8, n ¼ 3), whereas fluorocytes were
almost absent in the erythroblasts derived from N-CB
iPSC 10-f (2.6% 5 0.4, n ¼ 3, p < 0.001) (Figures 6B and
6C, upper panels). After gene therapy, metabolic correction
was easily demonstrated by the complete disappearance of
fluorocytes in the erythroid cells derived from the cor-
rected CEP-K iPSC clones 4-c and 4-i (4.3% 5 1.8 and
6.3% 5 3.5, respectively; p < 0.01 for both clones versus
the uncorrected CEP-K iPSC) (Figures 6B and 6C, lower
panels). These data demonstrate that a single HAUPins
proviral copy in CEP-K iPSC clones is sufficient to allow
a metabolic correction of erythroid cells by the disappear-
ance of 90% of porphyrins in erythroid cells.Discussion
We generated iPSCs from keratinocytes at a high efficiency
(up to 1.4% of input cells) with only two reprogramming
vectors. On the basis of our preliminary results, we chose
these cells because they had a reprogramming yield 103
higher and 2.53 faster than did human control fibroblasts.
The low endogenous expression of pluripotency markers
in keratinocytes is in agreement with the higher reprog-
ramming yield in these cells compared with fibroblasts in
our model. The efficiency of reprogramming human
keratinocytes has also been observed by others studying
normal and dystrophic-epidermolysis-bullosa-affected
individuals.38,39 The low endogenous expression of KLF4
and MYC in keratinocytes could also explain the ease
with which they are reprogramed.38
An efficient hematopoietic differentiation was obtained
from two independent N-CB iPSC clones and three
independent K iPSC clones. Interestingly, we found that
the MFI of CD34-APC signals was ten times higher in
the adherent fraction than in the nonadherent counter-
part, suggesting the presence of more primitive HSCs
in the adherent fraction, as previously observed by012
Figure 5. Efficient Erythroid Differentiation of HSCs Derived from iPSCs with Specific Transgene Expression
(A) Representative flow-cytometry data of in vitro erythroid-differentiation (ED) cultures from CEP-K iPSC 4-i. Cells were stained at day
10 and at day 17 of ED with anti-CD71-phycoerythrin (PE)- and anti-GPA-APC-conjugated antibodies (or they were stained with control
isotype antibodies conjugated with PE and APC; left panels).
(B) Erythroblast maturation was evaluated at day 24 of ED by staining with May-Gru¨nwald-Giemsa. Photographs show the late stage of
erythroid maturation.
(C) Schema of the proviral form of the HAEPins control vector containing EGFP under the control of the HS40/ankyrin erythroid
promoter.
(D) Representative FACS analysis of hematopoietic progenitors at day 21 of hematopoietic differentiation (HD) from the N-CB iPSCs
previously transduced with the HAEPins lentivector.
(E) At day 10 of HD, formation of early erythroblast cells was revealed by GFP expression in sacks on OP9 stroma (middle and left panels)
and by erythroblast cell suspension at day 21 of HD (right panel).
(F) Inverted microscopy of BFU-E colonies under a visible-light microscope (upper panels) and merged with GFP expression detected
under UV light (lower panels).
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AC
B Figure 6. Enzymatic and Metabolic
Correction
(A) UROS enzymatic activities in primary
N-K and deficient CEP-K cells and in
erythroid cells derived from N-CB iPSC
10-f, CEP-K iPSC 3 (uncorrected), and
CEP-K iPSC 4-i (corrected) clones.
(B) Bar graphs show average percentages
of fluorocytes gated on erythroid GPAþ
cells from three independent experiments
(mean5 SD).
(C) Representative FACS analysis of the
fluorocytes gated on erythroid GPAþ cells
derived from N-CB iPSC 10-f and uncor-
rected CEP-K iPSC 3 (upper panels) and
from two corrected clones (4-i and 4-c;
lower panels) at day 21of erythroid differen-
tiation.Woods et al.35 The type of donor cell can influence the epi-
genome and the differentiation potential of iPSCs.40,41
Hematopoietic differentiation was supposed to be more
efficient with iPSCs derived from cord blood than with
those derived from keratinocytes. Surprisingly, in our
study, CEP-K iPSCs did not show a hematopoietic differen-
tiation rate that was significantly different from that of N-
CB iPSCs. We believe that both downregulation of TP53
and forced expression of MYC are key requisites for erasing
the residual epigenetic memory of the primary source of
cells. Importantly, our experimental strategy was set to
excise the reprogramming vectors for the generation of
‘‘clean’’ iPSCs, i.e., those that are free of reprogramming
cassettes. Lack of the remaining reprogramming gene in
our iPSCs possibly prevents aberrant de novo methyla-
tions, which can be deleterious to efficient further differen-
tiation.41 Methylcellulose assays showed evidence that the
cells differentiated from both K iPSCs and N-CB iPSCs were
functional hematopoietic progenitors. We can conclude
that human primary keratinocytes are easily (1) available
from human skin, (2) reprogrammed, and (3) differenti-
ated in HSCs. Therefore, these cells are a very attractive
somatic cell source for iPSC-based gene therapy for hema-
topoietic disorders.118 The American Journal of Human Genetics 91, 109–121, July 13, 2012We also report a highly efficient
erythroid differentiation with HSCs
derived from iPSCs. The erythroid
specificity of our vector was demon-
strated by a GFP-expressing control
vector in which expression of the
reporter gene was restricted to GPAþ
cells. The UROS enzymatic activity
generated in erythroid cells was similar
to that previously observed in erythro-
blasts from normal primary CD34þ
peripheral-blood cells.42 A single copy
of this vector restored 11% of the
UROS enzymatic activity, whereas
one allele of the normal endogenous
erythroid-specific UROS restored 50%,suggesting that the endogenous UROS enhancer and
promoter is almost five times stronger than our enhancer
and promoter construct.43 However, this partial activity
(11% of the normal activity in erythroblasts) led to
a disappearance of 90% of fluorocytes and was then
enough to obtain a sufficient metabolic correction of the
disease. This is in agreement with recently published
results concerning a knockin CEPmouse model11 in which
the substitutions p.Cys73Arg (c.217T>C) and p.Val99Leu
(c.296G>C) described in this mouse model were associated
with 11% of wild-type UROS activity; the animals
were just very mildly anemic (hemoglobin: 14 g/dl). This
is also in agreement with clinical observations of the
absence of phenotypes or minor phenotypes in persons
with genotypes inducing residual UROS enzymatic
activity.44,45
In a 3 week protocol of in vitro erythroid differentiation,
iPSC-derived erythroid cells expressed the majority of fetal
hemoglobin (65%), as previously reported.27 This is prob-
ably due to an early stage of development, after only
21 days of culture. In vivo experiments in immunodefi-
cient NSG mice could be helpful for modeling long-term
erythroid differentiation with the use of iPSC clones
derived from CEP cells. However, current humanized
mice have not proved to be very useful in assessing human
red blood cell function because macrophages limit recon-
stitution of human red blood cells in them.46
In current HSC-based gene therapy, the recommended
transduction level is around 30%–40% so that multiple
integration events and associated oncogenic risks can be
avoided. However, in CEP, there is no metabolic cross-
correction between nontransduced and transduced
deficient cells, and the majority of cells have to be cor-
rected.47 Fortunately, we previously demonstrated that
gene therapy of CEP mice is facilitated by an in vivo
survival advantage of corrected erythroid cells: only 40%
of corrected cells were required for obtaining a complete
phenotypic correction.12 Therefore, for current CEP gene
therapy, a full conditioning regimen prior to grafting is
likely to be necessary. By contrast, a major advantage of
the iPSC clonal approach is that 100% of HSCs derived
from a genetically corrected clone are metabolically cor-
rected. Thus, reinjection of 100% of corrected cells with
their survival advantage allows us to consider only a partial
conditioning with the advantage of dramatically reducing
the morbidity risks of full conditioning.
For clinical applications, safe iPSC-based gene therapy
will require considerable efforts for establishing a sufficient
number of iPSC clones with (1) a normal karyotype, (2)
full pluripotential capability, (3) complete excision of
reprogramming cassettes, (4) only one proviral copy
number of therapeutic gene, and (5) a rare random GSH.
The reprogramming vectors used in this study were flanked
by two loxP sites in order to be excised by expression of
CRE recombinase. Thus, iPSCs free of potentially onco-
genic reprogramming genes could be obtained. We chose
adenovirus-mediated CRE transient expression with no
risk of genomic integration to obtain a fast and efficient
proviral excision. However, with this approach, small
DNA from RU5 and the two residual loxP sites (34 bp
each) still remains and could potentially cause deleterious
effects, such as alteration of regulatory sequences. For
clinical application, nonintegrative reprogramming
methods could be safer, even if the efficiency of these
methods is still very low. Furthermore, one advantage of
iPSC-based gene therapy is the clonal approach allowing
the characterization of the proviral IS of the therapeutic
gene. Here, the IS of the HAUPins vector was mapped by
LAM-PCR from the three corrected iPSC clones with only
one copy of the transgene. We characterized the exact
position of the IS: in both clones, the HAUPins vector
was located outside of the exons in the intronic regions
of nononcogenic genes (according to the allOnco data-
base). However, three proto-oncogenes were found in the
600 kb region surrounding the IS of both clones 4-c and
4-e. This method allows us to identify and eliminate
clones with potential oncogenic risk for clinical transla-
tion. The HAUPins vector used is a new generation of
lentiviral vector secured by an erythroid-specific promoter
and by the insertion of the efficient chicken hypersensitive
site 4 (cHS4) chromatin insulator in the DU3 sequenceThe Amfrom the 30 LTR. This insulator was designed to prevent
deregulation of neighboring genes.48,49 Interestingly, no
oncogene was found in the vicinity of the IS for the other
clone (4-i). These would-be ‘‘GSHs’’ defined by Papapetrou
et al.27 are relatively rare (fewer than 10% of ISs)29 and
require a tedious characterization of each IS. In the
same way, even the well-known safe AAVS1 locus does
not respect all these strict rules because two oncogenes
are in its vicinity and it even disrupts one gene.50 An
interesting alternative to lentiviral additive therapy for
clinical application could be to insert UROS cDNA by the
zinc finger nuclease (ZFN) strategy into GSHs chosen
in silico.50 Predicted high efficiency of this approach
will certainly overpass the rarity of random retroviral
ISs in GSHs. In the future, targeted repair of specific muta-
tions will be the ‘‘ideal’’ correction approach but will
require design of specific ZFNs for the most frequent
UROS mutations.
In conclusion, this study reports iPSC-based gene
therapy for porphyria. The next step of this project will
be to evaluate the interest of iPSC-gene therapy in our
CEP mouse model to study in vivo whether a long-term
enzymatic and metabolic correction is possible. Although
biosafety concerns still need to be addressed for clinical
translation, regenerative therapy for CEP and other genetic
red blood cell disorders is very promising.Supplemental Data
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